Search research articles
Contact Us
Filters
Showing results (61-70 of 90) with videos related to
Page
of 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 1998
Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers
I de Mascarel, F Bonichon, M Durand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 2002
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
A Howell, J F R Robertson, J Quaresma Albano, et al.
Breast Cancer Research and Treatment
|
August 15, 2000
Application of the van nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations
I de Mascarel, F Bonichon, G MacGrogan, et al.
Annals of the New York Academy of Sciences
|
November 30, 1993
Expression of the GST pi gene and response to tamoxifen therapy in locally advanced breast carcinomas
F Dorion-Bonnet, N Quénel, J M Coindre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2003
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study
P Therasse, L Mauriac, M Welnicka-Jaskiewicz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
J A Oshaughnessy, J Blum, V Moiseyenko, et al.
Bulletin Du Cancer
|
August 10, 2001
[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]
M Tubiana-Hulin, P Beuzeboc, L Mauriac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 1997
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer
M J Piccart, J Klijn, R Paridaens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 15, 2002
Oral vinorelbine: feasibility and safety profile
A Depierre, G Freyer, J Jassem, et al.
Bulletin Du Cancer
|
July 21, 2000
[Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC]
L Mauriac, M P Blanc-Vincent, E Luporsi, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 90) with videos related to
Sort By:
Page
of 9
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 1998
Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers
I de Mascarel, F Bonichon, M Durand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 2002
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
A Howell, J F R Robertson, J Quaresma Albano, et al.
Breast Cancer Research and Treatment
|
August 15, 2000
Application of the van nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations
I de Mascarel, F Bonichon, G MacGrogan, et al.
Annals of the New York Academy of Sciences
|
November 30, 1993
Expression of the GST pi gene and response to tamoxifen therapy in locally advanced breast carcinomas
F Dorion-Bonnet, N Quénel, J M Coindre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2003
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study
P Therasse, L Mauriac, M Welnicka-Jaskiewicz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
J A Oshaughnessy, J Blum, V Moiseyenko, et al.
Bulletin Du Cancer
|
August 10, 2001
[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]
M Tubiana-Hulin, P Beuzeboc, L Mauriac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 1997
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer
M J Piccart, J Klijn, R Paridaens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 15, 2002
Oral vinorelbine: feasibility and safety profile
A Depierre, G Freyer, J Jassem, et al.
Bulletin Du Cancer
|
July 21, 2000
[Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC]
L Mauriac, M P Blanc-Vincent, E Luporsi, et al.
Page
of 9